Search results
22 maj 2023 · Bullous systemic lupus erythematosus (BSLE) is a rare manifestation of systemic lupus erythematosus. It has clinical and histological features that may lead to misdiagnosis and delayed treatment of this easily treatable condition.
1 wrz 2021 · We recommend dapsone as second-line treatment in refractory CLE, especially bullous lesions of CLE or bullous systemic lupus erythematosus (BSLE), preferably in addition to antimalarials and systemic corticosteroids. (97% consensus) •
7 paź 2021 · Pharmacologic Therapy. Dapsone is the initial treatment of choice for bullous systemic lupus erythematosus. [2, 34] The response is usually dramatic, with cessation of new blister formation...
Immunoglobulin G. Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
31 paź 2014 · Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus erythematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
25 lut 2019 · She was initially treated with systemic prednisone and hydroxychloroquine. Her condition evolved with relapsing lesions, which required the introduction of Dapsone. The authors emphasize the relevance of recognizing BSLE—a rare presentation of SLE—which may evolve with marked clinical presentation.
What is the treatment for bullous systemic lupus erythematosus? Dapsone, at a dose of 1.0–1.5 mg/kg/day, is considered the treatment of choice. It is effective in the vast majority of patients and leads to rapid clinical improvement within days or a few weeks.
